About the project
The development of a human lung-on-a-chip model represents a cutting-edge approach for screening the antiviral properties of approved drugs in the context of COVID-19 treatment, as well as for future viral pandemics. This innovative model system mimics the physiological complexity of the human lung, allowing researchers to study the interactions between viral pathogens and human lung cells in a more accurate and controlled manner. By utilising this lung-on-a-chip technology, researchers can assess the efficacy of various approved drugs in combating viral infections, such as SARS-CoV-2, the causative agent of COVID-19. This approach enables rapid and cost-effective screening of a wide range of drugs, providing valuable data on their antiviral properties, potential side effects, and optimal dosing regimens. Additionally, the lung-on-a-chip model can be adapted to study other emerging viral pathogens, thereby serving as a versatile tool in the fight against future viral pandemics. The use of this advanced model system holds great promise for accelerating the drug discovery and development process, ultimately leading to the identification of effective treatments and interventions for COVID-19 and future viral outbreaks.
Funding
This work is funded by the Health Innovation and Wellbeing Community.
Contact
For further information contact the Principal Investigator Dr. Adele McCormick at [email protected].